Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic.

Slides:

Advertisements

Similar presentations

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Advertisements

LEUKEMIA & LYMPHOMA SOCIETY TEAM IN TRAINING. THE LEUKEMIA & LYMPHOMA SOCIETY WORLDS LARGEST VOLUNTARY HEALTH ORGANIZATION DEDICATED TO FUNDING BLOOD.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

What is LDN? It is a lower dosage of the FDA-approved drug, naltrexone which is used to treat heroin and opium addiction by blocking the body’s opioid.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),

Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),

Relation of H pylori infection to upper GI tract conditions

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

State of the Art in BRCA-Mutated Ovarian Cancer

Dose-escalation patient response.

Incidence of nonskin cancers at five years

Immunotherapy for lymphoma: The time is now

Chinese Benzene Cohort Study

EBV DNA: a Hodgkin lymphoma biomarker?

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Chemotherapy Day 2.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Acute leukemia: A pediatric perspective

Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

PARPi combinations against HR-proficient tumors.

Cancer Stem Cells in Hematopoietic Malignancies

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

CTCL: INNOVATIVE TREATMENTS GEMCITABINE

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

by Michael F. Leahy, and J. Harvey Turner

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

How I treat refractory CLL

(A,B) mRNA in situ hybridisation (ISH) with Epstein–Barr virus-encoded small RNA-1 probe in a case of Hodgkin’s lymphoma focally affecting the bone marrow.

Low SI on axial T2-weighted images as a sign of malignancy.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Figure 3 Clinical outcome of apheresis therapies for NMOSD attacks

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Clinical Lymphoma, Myeloma and Leukemia

Minimal Residual Disease and Hematologic Malignancies

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Frequent alterations identified and potential actionability.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Pros and cons for neoadjuvant immunotherapy.

Representative patient responses to ulixertinib.

Genomic determinants of response to cytotoxic chemotherapy.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Flow diagram of the patient cohort

Presentation transcript:

Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. AL, acute leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; NUT ca, NUT carcinoma; GLB, glioblastoma; GI, gastrointestinal; n, number of patients included; CR, complete remission; PR, partial remission; NR, no response. *This study included 70 patients at the time of reporting, and preliminary activity was reported in 10 patients with NUT carcinoma (67). Cited references: Berthon, et al. (60); Amorim, et al. (61); Stathis, et al. (64); Massard, et al. (65); Hottinger, et al. (69); Abramson, et al. (62); O'Dwyer, et al. (67); Shapiro, et al. (66); Postel-Vinay, et al. (70). Anastasios Stathis, and Francesco Bertoni Cancer Discov 2018;8:24-36 ©2018 by American Association for Cancer Research